Subscribe for the newsletter
Mobile Navigation
Subscribe for the Newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact US
HuidaGene Therapeutics
Drug Discovery & Development
Overview
Contact US
Contributions
Contributors
Contributions
1 Contributions
1 / 1
0 Contributors
1 / 0
1 / 1
1 / 0
Sign in
No authors found
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
